Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 7:31 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 118 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Varicella vaccine Clear all

Conditions: Hepatitis C
Interventions: Zoster vaccine live; Drug
Lead sponsor: Rockefeller University; Other
Eligibility: 50 Years to 60 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: Herpes Zoster
Interventions: Herpes Zoster Vaccine GSK1437173A; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 50 Years and older
Enrollment: 8,687 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 37
States / cities: Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 31 more

Conditions: Herpes Zoster
Interventions: Herpes Zoster Vaccine 1437173A, Placebo vaccine (saline); Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 11
States / cities: Little Rock, Arkansas • Duarte, California • San Francisco, California + 8 more

Conditions: Chickenpox
Interventions: Investigational varicella vaccine, Marketed varicella vaccine, Measles, mumps, and rubella vaccine, Hepatitis A vaccine, PCV (pneumococcal conjugate vaccine) 13, PCV 20, Vaxneuvance; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Months to 15 Months
Enrollment: 750 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 22
States / cities: Phoenix, Arizona • Tucson, Arizona • Huntington Park, California + 18 more

Conditions: Rheumatoid Arthritis, Varicella Zoster
Interventions: Zostavax (varicella zoster virus) vaccine; Drug
Lead sponsor: Oklahoma Medical Research Foundation; Other
Eligibility: 50 Years to 80 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2018
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Herpes Zoster, Herpes Zoster Vaccine
Interventions: Herpes Zoster Vaccine GSK1437173A; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 50 Years and older
Enrollment: 7,539 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2024
U.S. locations: 25
States / cities: Phoenix, Arizona • Spring Valley, California • Hallandale, Florida + 18 more

Conditions: Herpes Zoster
Interventions: Herpes Zoster vaccine GSK1437173A, Placebo; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 1,877 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 23
States / cities: Duarte, California • San Francisco, California • Aurora, Colorado + 16 more

Conditions: Meningitis, Meningococcal Infection
Interventions: MenACWY-CRM197, DTaP (Diptheria, Tetanus, Pertussis) Vaccine, Hib (Haemophilus influenza b) Vaccine, IPV (Inactivated Polio Vaccine) Vaccine, Pneumococcal conjugate Vaccine, MMR (Measles, Mumps, and Rubella) Vaccine, Varicella Vaccine, Hepatitis A Virus; Biological
Lead sponsor: Novartis; Industry
Eligibility: 55 Days to 89 Days
Enrollment: 7,744 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2011
U.S. locations: 130
States / cities: Birmingham, Alabama • Dothan, Alabama • Tuscon, Arizona + 107 more

Conditions: Persistence of Varicella Immunity
Interventions: Varicella vaccine; Biological
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 80 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Hepatitis A
Interventions: Havrix®, M-M-R®II, VARIVAX®; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Months to 13 Months
Enrollment: 1,474 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2009
U.S. locations: 42
States / cities: Cabot, Arkansas • Jonesboro, Arkansas • North Little Rock, Arkansas + 37 more

Conditions: Herpes Zoster
Interventions: HZ/su vaccine; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 50 Years and older
Enrollment: 3,038 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 8
States / cities: Phoenix, Arizona • Elkridge, Maryland • Charlotte, North Carolina + 5 more

Conditions: Herpes Zoster
Interventions: HZ/su, Flu D-QIV, mRNA-1273; Biological · Combination Product
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 2,013 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 46
States / cities: Tempe, Arizona • Oxnard, California • San Diego, California + 40 more

Conditions: Herpes Zoster
Interventions: Herpes Zoster Vaccine GSK1437173A, Placebo; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 50 Years and older
Enrollment: 16,165 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2015
U.S. locations: 43
States / cities: Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 36 more

Conditions: Measles, Measles-Mumps-Rubella+Chickenpox Vaccine
Interventions: MMRVNS, MMRV; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 15 Months to 6 Years
Enrollment: 1,209 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 17
States / cities: Birmingham, Alabama • Walnut Creek, California • Miami, Florida + 12 more

Conditions: Herpes Zoster
Interventions: Zostavax, Shingrix; Biological
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 50 Years to 85 Years
Enrollment: 105 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Herpes Zoster
Interventions: Herpes Zoster vaccine GSK 1437173A, GSK Biologicals' quadrivalent seasonal influenza vaccine FLU-D-QIV GSK2321138A; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 50 Years and older
Enrollment: 829 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 3
States / cities: Phoenix, Arizona • Carnegie, Pennsylvania • Erie, Pennsylvania

Conditions: Kidney Transplant Recipients
Interventions: Varivax®; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 2 Years to 21 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2001
U.S. locations: 4
States / cities: Birmingham, Alabama • Boston, Massachusetts • Ann Arbor, Michigan + 1 more

Conditions: Varicella
Interventions: VARIVAX® PE34 Process, VARIVAX® 2016 Commercial Process, M-M-R II®; Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 12 Months to 23 Months
Enrollment: 600 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 37
States / cities: Birmingham, Alabama • Jonesboro, Arkansas • Anaheim, California + 32 more

Conditions: Herpes Zoster
Interventions: Choosing to receive the vaccine; Other
Lead sponsor: NYU Langone Health; Other
Eligibility: 60 Years and older
Enrollment: 170 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 2
States / cities: New York, New York

Conditions: Chickenpox
Interventions: Investigational varicella vaccine low potency, Investigational varicella vaccine medium potency, Investigational varicella vaccine high potency, Licensed varicella vaccine Lot 1, Licensed varicella vaccine Lot 2, Measles, mumps, and rubella vaccine, Hepatitis A vaccine, 13-valent pneumococcal conjugate vaccine; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Months to 15 Months
Enrollment: 800 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 41
States / cities: Bryant, Arkansas • Jonesboro, Arkansas • Little Rock, Arkansas + 37 more

Conditions: Pneumococcal Immunization
Interventions: PCV21 vaccine, Prevnar 20 vaccine, M-M-R II vaccine, Rotarix, RotaTeq, Vaxelis vaccine, Varivax, Priorix, VAQTA, Havrix; Biological
Lead sponsor: Sanofi; Industry
Eligibility: 42 Days to 89 Days
Enrollment: 580 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 17
States / cities: Los Angeles, California • Hollywood, Florida • Miami, Florida + 13 more

Conditions: RSV Immunization
Interventions: RSVt vaccine, Diphtheria, tetanus, pertussis, poliomyelitis , Haemophilus influenzae type b, and hepatitis B vaccine, Diphtheria, tetanus, pertussis, Haemophilus influenzae type b and poliomyelitis vaccine, Hepatitis B vaccine, Streptococcus pneumoniae vaccine, Rotavirus vaccine, Measles, mumps, and rubella vaccine, Varicella virus vaccine, Placebo; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 6 Months to 12 Months
Enrollment: 2,226 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 66
States / cities: Birmingham, Alabama • Grand Bay, Alabama • Mobile, Alabama + 55 more

Conditions: Measles; Mumps; Rubella; Chickenpox, Measles
Interventions: Investigational MMRV(H)NS vaccine, Investigational MM(H)RVNS vaccine, Investigational M(L)M(L)R(L)V(L)NS vaccine, Marketed MMRV_Lot 1 and Lot 2 vaccine; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 4 Years to 6 Years
Enrollment: 801 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 35
States / cities: Birmingham, Alabama • Jonesboro, Arkansas • Bellflower, California + 30 more

Conditions: Herpes Zoster
Interventions: GSK Biologicals Herpes Zoster subunit (HZ/su) vaccine (GSK 1437173A); Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 65 Years and older
Enrollment: 430 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 32
States / cities: Huntsville, Alabama • Daly City, California • Los Gatos, California + 27 more

Search by objective public record fields.

Effects of Chronic Viral Infection on Immune Response to Zoster Vaccination

Cross-vaccination Study of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK 1437173A) in Subjects Who Previously Received Placebo in ZOSTER-006 (NCT01165177) and ZOSTER-022 (NCT01165229) Studies.

Safety & Immunogenicity of GlaxoSmithKline Biologicals' Herpes Zoster Vaccine 1437173A

A Study on the Safety of an Investigational Chickenpox Vaccine, When Given to Healthy Children, 12 to 15 Months of Age

Safety of Zostavax Vaccination in Rheumatoid Arthritis

A Long-term Follow-up Study (ZOE-LTFU) of Two Studies 110390 (ZOSTER-006) and 113077 (ZOSTER-022) to Assess the Efficacy, Safety, and Immunogenicity Persistence of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine and Assessment of 1 or 2 Additional Doses in Two Subgroups of Older Adults

Study to Evaluate Efficacy, Safety, and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A

Study to Evaluate the Safety of Novartis MenACWY Conjugate Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants

Persistence of Varicella Immunity in Hospital Employees Receiving Varicella Vaccine

Immunogenicity & Safety of Hepatitis A Vaccine Co-admin With a Measles/Mumps/Rubella & a Varicella Vaccine in Children

A Study on the Long-term Efficacy, Safety and Persistence of Immune Response of a Vaccine Against Herpes Zoster in Older Adults

A Study on the Immune Response and Safety of the Shingles Vaccine and the Influenza Vaccine When Either is Given to Healthy Adults at the Same Time or Following a COVID-19 Booster Vaccine

Study to Evaluate Efficacy, Safety and Immunogenicity of GSK Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults Aged 50 Years and Older

A Study on the Immune Response and Safety of an Investigational Combined Measles, Mumps, Rubella and Varicella Vaccine, When Administered as Intramuscular Injection to Healthy Children 15 Months to 6 Years of Age

Persistence of Protection by Shingrix

Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With GSK Biologicals' Seasonal Influenza Vaccine GSK2321138A in Adults Aged 50 Years and Older

Evaluation of the Safety of Varivax® in Pediatric Renal Transplant Recipients

Evaluation of Immunogenicity and Safety of VARIVAX® Passage Extension 34 (PE34) Process in Children (V210-A03)

Increasing Use of the Vaccine Against Herpes Zoster/Shingles at NYULMC and Bellevue Hospital

A Study on the Immune Response and Safety of Various Potencies of an Investigational Chickenpox Vaccine Compared With a Marketed Chickenpox Vaccine, Given to Healthy Children 12 to 15 Months of Age

Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age

Co-administration Study of an Investigational Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers

A Study on the Immune Response and Safety of a Combined Measles, Mumps, Rubella, Chickenpox Vaccine Compared to a Marketed Combined Vaccine, Given to Healthy Children 4 to 6 Years of Age

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) in Adults ≥ 65 Years of Age With and Without Zostavax® Vaccination at Least 5 Years Earlier